nodes	percent_of_prediction	percent_of_DWPC	metapath
Aprepitant—CYP3A7-CYP3A51P—Tretinoin—peripheral nervous system neoplasm	0.082	0.137	CbGbCtD
Aprepitant—CYP3A7—Tretinoin—peripheral nervous system neoplasm	0.082	0.137	CbGbCtD
Aprepitant—CYP3A5—Tretinoin—peripheral nervous system neoplasm	0.0615	0.103	CbGbCtD
Aprepitant—CYP1A2—Alitretinoin—peripheral nervous system neoplasm	0.0493	0.0821	CbGbCtD
Aprepitant—CYP2C9—Tretinoin—peripheral nervous system neoplasm	0.0413	0.0688	CbGbCtD
Aprepitant—CYP1A2—Dacarbazine—peripheral nervous system neoplasm	0.0394	0.0657	CbGbCtD
Aprepitant—CYP3A7-CYP3A51P—Vincristine—peripheral nervous system neoplasm	0.0377	0.0628	CbGbCtD
Aprepitant—CYP3A7—Vincristine—peripheral nervous system neoplasm	0.0377	0.0628	CbGbCtD
Aprepitant—CYP3A5—Vincristine—peripheral nervous system neoplasm	0.0283	0.0471	CbGbCtD
Aprepitant—CYP3A5—Etoposide—peripheral nervous system neoplasm	0.0259	0.0432	CbGbCtD
Aprepitant—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0258	0.043	CbGbCtD
Aprepitant—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.024	0.04	CbGbCtD
Aprepitant—CYP1A2—Etoposide—peripheral nervous system neoplasm	0.0193	0.0321	CbGbCtD
Aprepitant—CYP2C9—Cisplatin—peripheral nervous system neoplasm	0.0177	0.0295	CbGbCtD
Aprepitant—TACR1—trigeminal nerve—peripheral nervous system neoplasm	0.0151	0.242	CbGeAlD
Aprepitant—TACR1—vagus nerve—peripheral nervous system neoplasm	0.0141	0.226	CbGeAlD
Aprepitant—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.011	0.0184	CbGbCtD
Aprepitant—TACR1—cranial nerve—peripheral nervous system neoplasm	0.0108	0.172	CbGeAlD
Aprepitant—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.0101	0.0168	CbGbCtD
Aprepitant—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00689	0.0115	CbGbCtD
Aprepitant—TACR3—brainstem—peripheral nervous system neoplasm	0.00611	0.0979	CbGeAlD
Aprepitant—TACR1—nerve—peripheral nervous system neoplasm	0.00551	0.0883	CbGeAlD
Aprepitant—TACR1—ganglion—peripheral nervous system neoplasm	0.00544	0.0872	CbGeAlD
Aprepitant—TACR3—cerebellum—peripheral nervous system neoplasm	0.00301	0.0483	CbGeAlD
Aprepitant—TACR1—brainstem—peripheral nervous system neoplasm	0.00237	0.0379	CbGeAlD
Aprepitant—TACR1—SIDS Susceptibility Pathways—PHOX2B—peripheral nervous system neoplasm	0.00109	0.0485	CbGpPWpGaD
Aprepitant—TACR3—G alpha (q) signalling events—NTS—peripheral nervous system neoplasm	0.00106	0.0471	CbGpPWpGaD
Aprepitant—TACR3—Peptide ligand-binding receptors—NTS—peripheral nervous system neoplasm	0.00104	0.0465	CbGpPWpGaD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—NTS—peripheral nervous system neoplasm	0.000946	0.0421	CbGpPWpGaD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000701	0.0312	CbGpPWpGaD
Aprepitant—CYP3A5—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	0.000546	0.0243	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000534	0.0238	CbGpPWpGaD
Aprepitant—TACR1—G alpha (q) signalling events—NTS—peripheral nervous system neoplasm	0.000517	0.023	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000512	0.0228	CbGpPWpGaD
Aprepitant—TACR1—Peptide ligand-binding receptors—NTS—peripheral nervous system neoplasm	0.00051	0.0227	CbGpPWpGaD
Aprepitant—TACR3—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	0.000475	0.0212	CbGpPWpGaD
Aprepitant—TACR3—Peptide ligand-binding receptors—KNG1—peripheral nervous system neoplasm	0.000469	0.0209	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—NTS—peripheral nervous system neoplasm	0.000462	0.0206	CbGpPWpGaD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	0.000425	0.0189	CbGpPWpGaD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000342	0.0152	CbGpPWpGaD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000315	0.014	CbGpPWpGaD
Aprepitant—TACR1—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	0.000314	0.014	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000302	0.0134	CbGpPWpGaD
Aprepitant—CYP3A4—Codeine and Morphine Metabolism—ABCB1—peripheral nervous system neoplasm	0.000299	0.0133	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—BDNF—peripheral nervous system neoplasm	0.000293	0.013	CbGpPWpGaD
Aprepitant—TACR1—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	0.000288	0.0128	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000274	0.0122	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000263	0.0117	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000261	0.0116	CbGpPWpGaD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	0.000258	0.0115	CbGpPWpGaD
Aprepitant—CYP3A4—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	0.000254	0.0113	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.00025	0.0111	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.00024	0.0107	CbGpPWpGaD
Aprepitant—TACR1—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	0.000234	0.0104	CbGpPWpGaD
Aprepitant—TACR1—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	0.000232	0.0103	CbGpPWpGaD
Aprepitant—TACR1—Peptide ligand-binding receptors—KNG1—peripheral nervous system neoplasm	0.000229	0.0102	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000229	0.0102	CbGpPWpGaD
Aprepitant—CYP3A5—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000212	0.00945	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.00021	0.00934	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	0.000208	0.00925	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000208	0.00924	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000192	0.00853	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—NF1—peripheral nervous system neoplasm	0.00018	0.00802	CbGpPWpGaD
Aprepitant—CYP2C19—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000164	0.00731	CbGpPWpGaD
Aprepitant—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—peripheral nervous system neoplasm	0.000164	0.00729	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000162	0.0072	CbGpPWpGaD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	0.000155	0.00692	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000155	0.00691	CbGpPWpGaD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000154	0.00685	CbGpPWpGaD
Aprepitant—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.00015	0.00666	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000147	0.00656	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—CASP3—peripheral nervous system neoplasm	0.000146	0.00651	CbGpPWpGaD
Aprepitant—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000143	0.00635	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000136	0.00603	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000134	0.00595	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000128	0.00571	CbGpPWpGaD
Aprepitant—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000127	0.000404	CcSEcCtD
Aprepitant—Gastritis—Doxorubicin—peripheral nervous system neoplasm	0.000127	0.000404	CcSEcCtD
Aprepitant—Pain—Cisplatin—peripheral nervous system neoplasm	0.000127	0.000403	CcSEcCtD
Aprepitant—Muscular weakness—Doxorubicin—peripheral nervous system neoplasm	0.000127	0.000402	CcSEcCtD
Aprepitant—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000127	0.000402	CcSEcCtD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	0.000126	0.00562	CbGpPWpGaD
Aprepitant—Neutropenia—Epirubicin—peripheral nervous system neoplasm	0.000126	0.000398	CcSEcCtD
Aprepitant—Dysuria—Epirubicin—peripheral nervous system neoplasm	0.000126	0.000398	CcSEcCtD
Aprepitant—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000125	0.000397	CcSEcCtD
Aprepitant—Abdominal distension—Doxorubicin—peripheral nervous system neoplasm	0.000125	0.000397	CcSEcCtD
Aprepitant—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.000125	0.000396	CcSEcCtD
Aprepitant—Dysphagia—Doxorubicin—peripheral nervous system neoplasm	0.000124	0.000394	CcSEcCtD
Aprepitant—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	0.000124	0.000393	CcSEcCtD
Aprepitant—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000124	0.000393	CcSEcCtD
Aprepitant—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000124	0.000392	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.000123	0.00548	CbGpPWpGaD
Aprepitant—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	0.000123	0.000389	CcSEcCtD
Aprepitant—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000123	0.000389	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000123	0.00546	CbGpPWpGaD
Aprepitant—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000122	0.000388	CcSEcCtD
Aprepitant—Weight increased—Epirubicin—peripheral nervous system neoplasm	0.000122	0.000388	CcSEcCtD
Aprepitant—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000122	0.00542	CbGpPWpGaD
Aprepitant—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.000122	0.000385	CcSEcCtD
Aprepitant—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000122	0.000385	CcSEcCtD
Aprepitant—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	0.000121	0.000384	CcSEcCtD
Aprepitant—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000121	0.000384	CcSEcCtD
Aprepitant—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000121	0.000383	CcSEcCtD
Aprepitant—Pneumonia—Epirubicin—peripheral nervous system neoplasm	0.000121	0.000382	CcSEcCtD
Aprepitant—Infestation—Epirubicin—peripheral nervous system neoplasm	0.00012	0.00038	CcSEcCtD
Aprepitant—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.00012	0.00038	CcSEcCtD
Aprepitant—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.00012	0.00038	CcSEcCtD
Aprepitant—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000119	0.000379	CcSEcCtD
Aprepitant—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	0.000119	0.000377	CcSEcCtD
Aprepitant—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000119	0.000376	CcSEcCtD
Aprepitant—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000119	0.000376	CcSEcCtD
Aprepitant—TACR3—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.000118	0.00528	CbGpPWpGaD
Aprepitant—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000118	0.000373	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000118	0.000373	CcSEcCtD
Aprepitant—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000118	0.000373	CcSEcCtD
Aprepitant—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000118	0.000373	CcSEcCtD
Aprepitant—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	0.000117	0.000372	CcSEcCtD
Aprepitant—TACR1—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000117	0.00521	CbGpPWpGaD
Aprepitant—TACR1—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	0.000117	0.00521	CbGpPWpGaD
Aprepitant—Stomatitis—Epirubicin—peripheral nervous system neoplasm	0.000117	0.00037	CcSEcCtD
Aprepitant—Pain—Etoposide—peripheral nervous system neoplasm	0.000117	0.00037	CcSEcCtD
Aprepitant—Constipation—Etoposide—peripheral nervous system neoplasm	0.000117	0.00037	CcSEcCtD
Aprepitant—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000116	0.000369	CcSEcCtD
Aprepitant—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	0.000116	0.000369	CcSEcCtD
Aprepitant—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	0.000116	0.000369	CcSEcCtD
Aprepitant—Dysuria—Doxorubicin—peripheral nervous system neoplasm	0.000116	0.000369	CcSEcCtD
Aprepitant—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000116	0.000366	CcSEcCtD
Aprepitant—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000115	0.000366	CcSEcCtD
Aprepitant—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000115	0.000365	CcSEcCtD
Aprepitant—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	0.000115	0.000364	CcSEcCtD
Aprepitant—Haematuria—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000362	CcSEcCtD
Aprepitant—TACR1—Spinal Cord Injury—MYC—peripheral nervous system neoplasm	0.000114	0.00509	CbGpPWpGaD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	0.000114	0.00506	CbGpPWpGaD
Aprepitant—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	0.000113	0.00036	CcSEcCtD
Aprepitant—Weight increased—Doxorubicin—peripheral nervous system neoplasm	0.000113	0.000359	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000113	0.00504	CbGpPWpGaD
Aprepitant—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	0.000112	0.000357	CcSEcCtD
Aprepitant—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000112	0.000356	CcSEcCtD
Aprepitant—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.000112	0.000356	CcSEcCtD
Aprepitant—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000112	0.000355	CcSEcCtD
Aprepitant—TACR1—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000112	0.00497	CbGpPWpGaD
Aprepitant—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	0.000112	0.000353	CcSEcCtD
Aprepitant—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000111	0.000353	CcSEcCtD
Aprepitant—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000111	0.000353	CcSEcCtD
Aprepitant—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000111	0.000352	CcSEcCtD
Aprepitant—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.000111	0.000351	CcSEcCtD
Aprepitant—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.000111	0.000351	CcSEcCtD
Aprepitant—Rash—Alitretinoin—peripheral nervous system neoplasm	0.00011	0.000349	CcSEcCtD
Aprepitant—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.00011	0.000349	CcSEcCtD
Aprepitant—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	0.00011	0.000348	CcSEcCtD
Aprepitant—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.00011	0.000348	CcSEcCtD
Aprepitant—Bradycardia—Epirubicin—peripheral nervous system neoplasm	0.00011	0.000347	CcSEcCtD
Aprepitant—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000109	0.000347	CcSEcCtD
Aprepitant—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.000109	0.000345	CcSEcCtD
Aprepitant—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000109	0.000344	CcSEcCtD
Aprepitant—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000108	0.000343	CcSEcCtD
Aprepitant—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	0.000108	0.000343	CcSEcCtD
Aprepitant—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000108	0.000342	CcSEcCtD
Aprepitant—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000108	0.000342	CcSEcCtD
Aprepitant—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000108	0.000342	CcSEcCtD
Aprepitant—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	0.000108	0.000342	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000108	0.00479	CbGpPWpGaD
Aprepitant—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	0.000107	0.000339	CcSEcCtD
Aprepitant—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000107	0.000339	CcSEcCtD
Aprepitant—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000107	0.000338	CcSEcCtD
Aprepitant—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000107	0.000338	CcSEcCtD
Aprepitant—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000106	0.000337	CcSEcCtD
Aprepitant—Rash—Vincristine—peripheral nervous system neoplasm	0.000106	0.000336	CcSEcCtD
Aprepitant—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000106	0.000336	CcSEcCtD
Aprepitant—Haematuria—Doxorubicin—peripheral nervous system neoplasm	0.000106	0.000335	CcSEcCtD
Aprepitant—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.000106	0.000335	CcSEcCtD
Aprepitant—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000105	0.000334	CcSEcCtD
Aprepitant—Headache—Vincristine—peripheral nervous system neoplasm	0.000105	0.000334	CcSEcCtD
Aprepitant—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000104	0.000329	CcSEcCtD
Aprepitant—TACR1—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000102	0.00456	CbGpPWpGaD
Aprepitant—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000102	0.000323	CcSEcCtD
Aprepitant—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	0.000102	0.000322	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000101	0.00451	CbGpPWpGaD
Aprepitant—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	0.000101	0.000321	CcSEcCtD
Aprepitant—Eye disorder—Epirubicin—peripheral nervous system neoplasm	0.000101	0.000319	CcSEcCtD
Aprepitant—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.0001	0.000318	CcSEcCtD
Aprepitant—Tinnitus—Epirubicin—peripheral nervous system neoplasm	0.0001	0.000318	CcSEcCtD
Aprepitant—Nausea—Vincristine—peripheral nervous system neoplasm	0.0001	0.000317	CcSEcCtD
Aprepitant—Flushing—Epirubicin—peripheral nervous system neoplasm	9.98e-05	0.000316	CcSEcCtD
Aprepitant—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	9.98e-05	0.000316	CcSEcCtD
Aprepitant—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	9.9e-05	0.000314	CcSEcCtD
Aprepitant—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	9.88e-05	0.000313	CcSEcCtD
Aprepitant—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	9.87e-05	0.00439	CbGpPWpGaD
Aprepitant—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	9.83e-05	0.000312	CcSEcCtD
Aprepitant—Asthenia—Etoposide—peripheral nervous system neoplasm	9.78e-05	0.00031	CcSEcCtD
Aprepitant—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	9.78e-05	0.00031	CcSEcCtD
Aprepitant—Angiopathy—Epirubicin—peripheral nervous system neoplasm	9.76e-05	0.000309	CcSEcCtD
Aprepitant—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	9.76e-05	0.000309	CcSEcCtD
Aprepitant—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	9.72e-05	0.000308	CcSEcCtD
Aprepitant—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	9.69e-05	0.000307	CcSEcCtD
Aprepitant—Chills—Epirubicin—peripheral nervous system neoplasm	9.65e-05	0.000306	CcSEcCtD
Aprepitant—Pruritus—Etoposide—peripheral nervous system neoplasm	9.65e-05	0.000306	CcSEcCtD
Aprepitant—Alopecia—Epirubicin—peripheral nervous system neoplasm	9.51e-05	0.000301	CcSEcCtD
Aprepitant—Vomiting—Cisplatin—peripheral nervous system neoplasm	9.46e-05	0.0003	CcSEcCtD
Aprepitant—Mental disorder—Epirubicin—peripheral nervous system neoplasm	9.42e-05	0.000299	CcSEcCtD
Aprepitant—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	9.41e-05	0.000298	CcSEcCtD
Aprepitant—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	9.4e-05	0.00419	CbGpPWpGaD
Aprepitant—Rash—Cisplatin—peripheral nervous system neoplasm	9.38e-05	0.000297	CcSEcCtD
Aprepitant—TACR1—Spinal Cord Injury—TP53—peripheral nervous system neoplasm	9.38e-05	0.00418	CbGpPWpGaD
Aprepitant—Dermatitis—Cisplatin—peripheral nervous system neoplasm	9.37e-05	0.000297	CcSEcCtD
Aprepitant—Erythema—Epirubicin—peripheral nervous system neoplasm	9.36e-05	0.000297	CcSEcCtD
Aprepitant—Malnutrition—Epirubicin—peripheral nervous system neoplasm	9.36e-05	0.000297	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	9.35e-05	0.00416	CbGpPWpGaD
Aprepitant—Diarrhoea—Etoposide—peripheral nervous system neoplasm	9.33e-05	0.000296	CcSEcCtD
Aprepitant—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	9.3e-05	0.000295	CcSEcCtD
Aprepitant—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	9.28e-05	0.000294	CcSEcCtD
Aprepitant—Flushing—Doxorubicin—peripheral nervous system neoplasm	9.24e-05	0.000293	CcSEcCtD
Aprepitant—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	9.24e-05	0.000293	CcSEcCtD
Aprepitant—Flatulence—Epirubicin—peripheral nervous system neoplasm	9.23e-05	0.000292	CcSEcCtD
Aprepitant—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	9.17e-05	0.000291	CcSEcCtD
Aprepitant—Back pain—Epirubicin—peripheral nervous system neoplasm	9.06e-05	0.000287	CcSEcCtD
Aprepitant—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	9.03e-05	0.000286	CcSEcCtD
Aprepitant—Dizziness—Etoposide—peripheral nervous system neoplasm	9.02e-05	0.000286	CcSEcCtD
Aprepitant—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	9e-05	0.000285	CcSEcCtD
Aprepitant—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	8.99e-05	0.000285	CcSEcCtD
Aprepitant—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	8.97e-05	0.000284	CcSEcCtD
Aprepitant—Chills—Doxorubicin—peripheral nervous system neoplasm	8.93e-05	0.000283	CcSEcCtD
Aprepitant—Nausea—Cisplatin—peripheral nervous system neoplasm	8.84e-05	0.00028	CcSEcCtD
Aprepitant—Alopecia—Doxorubicin—peripheral nervous system neoplasm	8.79e-05	0.000279	CcSEcCtD
Aprepitant—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	8.72e-05	0.000276	CcSEcCtD
Aprepitant—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	8.69e-05	0.000275	CcSEcCtD
Aprepitant—Vomiting—Etoposide—peripheral nervous system neoplasm	8.67e-05	0.000275	CcSEcCtD
Aprepitant—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	8.66e-05	0.000275	CcSEcCtD
Aprepitant—Erythema—Doxorubicin—peripheral nervous system neoplasm	8.66e-05	0.000275	CcSEcCtD
Aprepitant—Anaemia—Epirubicin—peripheral nervous system neoplasm	8.65e-05	0.000274	CcSEcCtD
Aprepitant—Rash—Etoposide—peripheral nervous system neoplasm	8.6e-05	0.000272	CcSEcCtD
Aprepitant—Dermatitis—Etoposide—peripheral nervous system neoplasm	8.59e-05	0.000272	CcSEcCtD
Aprepitant—Headache—Etoposide—peripheral nervous system neoplasm	8.54e-05	0.000271	CcSEcCtD
Aprepitant—Flatulence—Doxorubicin—peripheral nervous system neoplasm	8.54e-05	0.000271	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	8.5e-05	0.00378	CbGpPWpGaD
Aprepitant—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	8.48e-05	0.000269	CcSEcCtD
Aprepitant—Malaise—Epirubicin—peripheral nervous system neoplasm	8.44e-05	0.000268	CcSEcCtD
Aprepitant—Syncope—Epirubicin—peripheral nervous system neoplasm	8.4e-05	0.000266	CcSEcCtD
Aprepitant—Back pain—Doxorubicin—peripheral nervous system neoplasm	8.38e-05	0.000266	CcSEcCtD
Aprepitant—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	8.33e-05	0.000264	CcSEcCtD
Aprepitant—Palpitations—Epirubicin—peripheral nervous system neoplasm	8.27e-05	0.000262	CcSEcCtD
Aprepitant—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	8.23e-05	0.000261	CcSEcCtD
Aprepitant—Cough—Epirubicin—peripheral nervous system neoplasm	8.17e-05	0.000259	CcSEcCtD
Aprepitant—Convulsion—Epirubicin—peripheral nervous system neoplasm	8.11e-05	0.000257	CcSEcCtD
Aprepitant—Nausea—Etoposide—peripheral nervous system neoplasm	8.1e-05	0.000257	CcSEcCtD
Aprepitant—Hypertension—Epirubicin—peripheral nervous system neoplasm	8.08e-05	0.000256	CcSEcCtD
Aprepitant—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	8.04e-05	0.000255	CcSEcCtD
Aprepitant—Anaemia—Doxorubicin—peripheral nervous system neoplasm	8.01e-05	0.000254	CcSEcCtD
Aprepitant—Arthralgia—Epirubicin—peripheral nervous system neoplasm	7.97e-05	0.000253	CcSEcCtD
Aprepitant—Chest pain—Epirubicin—peripheral nervous system neoplasm	7.97e-05	0.000253	CcSEcCtD
Aprepitant—Myalgia—Epirubicin—peripheral nervous system neoplasm	7.97e-05	0.000253	CcSEcCtD
Aprepitant—Anxiety—Epirubicin—peripheral nervous system neoplasm	7.94e-05	0.000252	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	7.92e-05	0.000251	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—NTS—peripheral nervous system neoplasm	7.9e-05	0.00352	CbGpPWpGaD
Aprepitant—Discomfort—Epirubicin—peripheral nervous system neoplasm	7.88e-05	0.00025	CcSEcCtD
Aprepitant—Malaise—Doxorubicin—peripheral nervous system neoplasm	7.81e-05	0.000248	CcSEcCtD
Aprepitant—Dry mouth—Epirubicin—peripheral nervous system neoplasm	7.8e-05	0.000247	CcSEcCtD
Aprepitant—Syncope—Doxorubicin—peripheral nervous system neoplasm	7.77e-05	0.000246	CcSEcCtD
Aprepitant—Confusional state—Epirubicin—peripheral nervous system neoplasm	7.71e-05	0.000244	CcSEcCtD
Aprepitant—Palpitations—Doxorubicin—peripheral nervous system neoplasm	7.66e-05	0.000243	CcSEcCtD
Aprepitant—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	7.64e-05	0.000242	CcSEcCtD
Aprepitant—Oedema—Epirubicin—peripheral nervous system neoplasm	7.64e-05	0.000242	CcSEcCtD
Aprepitant—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	7.61e-05	0.000241	CcSEcCtD
Aprepitant—Infection—Epirubicin—peripheral nervous system neoplasm	7.59e-05	0.000241	CcSEcCtD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	7.59e-05	0.00338	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CD55—peripheral nervous system neoplasm	7.57e-05	0.00337	CbGpPWpGaD
Aprepitant—Cough—Doxorubicin—peripheral nervous system neoplasm	7.56e-05	0.00024	CcSEcCtD
Aprepitant—Shock—Epirubicin—peripheral nervous system neoplasm	7.52e-05	0.000238	CcSEcCtD
Aprepitant—Convulsion—Doxorubicin—peripheral nervous system neoplasm	7.51e-05	0.000238	CcSEcCtD
Aprepitant—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	7.49e-05	0.000238	CcSEcCtD
Aprepitant—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	7.48e-05	0.000237	CcSEcCtD
Aprepitant—Hypertension—Doxorubicin—peripheral nervous system neoplasm	7.48e-05	0.000237	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	7.48e-05	0.00333	CbGpPWpGaD
Aprepitant—Tachycardia—Epirubicin—peripheral nervous system neoplasm	7.46e-05	0.000236	CcSEcCtD
Aprepitant—Skin disorder—Epirubicin—peripheral nervous system neoplasm	7.42e-05	0.000235	CcSEcCtD
Aprepitant—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	7.39e-05	0.000234	CcSEcCtD
Aprepitant—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	7.38e-05	0.000234	CcSEcCtD
Aprepitant—Chest pain—Doxorubicin—peripheral nervous system neoplasm	7.38e-05	0.000234	CcSEcCtD
Aprepitant—Myalgia—Doxorubicin—peripheral nervous system neoplasm	7.38e-05	0.000234	CcSEcCtD
Aprepitant—Anxiety—Doxorubicin—peripheral nervous system neoplasm	7.35e-05	0.000233	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	7.33e-05	0.000232	CcSEcCtD
Aprepitant—Discomfort—Doxorubicin—peripheral nervous system neoplasm	7.29e-05	0.000231	CcSEcCtD
Aprepitant—Anorexia—Epirubicin—peripheral nervous system neoplasm	7.28e-05	0.000231	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—KNG1—peripheral nervous system neoplasm	7.27e-05	0.00324	CbGpPWpGaD
Aprepitant—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	7.21e-05	0.000229	CcSEcCtD
Aprepitant—Hypotension—Epirubicin—peripheral nervous system neoplasm	7.14e-05	0.000226	CcSEcCtD
Aprepitant—Confusional state—Doxorubicin—peripheral nervous system neoplasm	7.13e-05	0.000226	CcSEcCtD
Aprepitant—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	7.07e-05	0.000224	CcSEcCtD
Aprepitant—Oedema—Doxorubicin—peripheral nervous system neoplasm	7.07e-05	0.000224	CcSEcCtD
Aprepitant—Infection—Doxorubicin—peripheral nervous system neoplasm	7.02e-05	0.000223	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	6.96e-05	0.000221	CcSEcCtD
Aprepitant—Shock—Doxorubicin—peripheral nervous system neoplasm	6.96e-05	0.000221	CcSEcCtD
Aprepitant—CYP3A7—Metabolism—PPIP5K2—peripheral nervous system neoplasm	6.95e-05	0.00309	CbGpPWpGaD
Aprepitant—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	6.93e-05	0.00022	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	6.93e-05	0.00308	CbGpPWpGaD
Aprepitant—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	6.92e-05	0.000219	CcSEcCtD
Aprepitant—Insomnia—Epirubicin—peripheral nervous system neoplasm	6.91e-05	0.000219	CcSEcCtD
Aprepitant—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	6.9e-05	0.000219	CcSEcCtD
Aprepitant—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	6.87e-05	0.000218	CcSEcCtD
Aprepitant—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	6.86e-05	0.000218	CcSEcCtD
Aprepitant—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	6.84e-05	0.000217	CcSEcCtD
Aprepitant—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	6.81e-05	0.000216	CcSEcCtD
Aprepitant—Somnolence—Epirubicin—peripheral nervous system neoplasm	6.79e-05	0.000215	CcSEcCtD
Aprepitant—Anorexia—Doxorubicin—peripheral nervous system neoplasm	6.74e-05	0.000214	CcSEcCtD
Aprepitant—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	6.73e-05	0.000213	CcSEcCtD
Aprepitant—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	6.64e-05	0.000211	CcSEcCtD
Aprepitant—TACR1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	6.62e-05	0.00295	CbGpPWpGaD
Aprepitant—Hypotension—Doxorubicin—peripheral nervous system neoplasm	6.61e-05	0.000209	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	6.6e-05	0.000209	CcSEcCtD
Aprepitant—Fatigue—Epirubicin—peripheral nervous system neoplasm	6.59e-05	0.000209	CcSEcCtD
Aprepitant—Pain—Epirubicin—peripheral nervous system neoplasm	6.54e-05	0.000207	CcSEcCtD
Aprepitant—Constipation—Epirubicin—peripheral nervous system neoplasm	6.54e-05	0.000207	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	6.44e-05	0.000204	CcSEcCtD
Aprepitant—Insomnia—Doxorubicin—peripheral nervous system neoplasm	6.4e-05	0.000203	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—GNAS—peripheral nervous system neoplasm	6.36e-05	0.00283	CbGpPWpGaD
Aprepitant—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	6.35e-05	0.000201	CcSEcCtD
Aprepitant—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	6.3e-05	0.0002	CcSEcCtD
Aprepitant—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	6.3e-05	0.0002	CcSEcCtD
Aprepitant—Somnolence—Doxorubicin—peripheral nervous system neoplasm	6.29e-05	0.000199	CcSEcCtD
Aprepitant—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	6.25e-05	0.000198	CcSEcCtD
Aprepitant—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	6.22e-05	0.000197	CcSEcCtD
Aprepitant—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	6.15e-05	0.000195	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	6.1e-05	0.000193	CcSEcCtD
Aprepitant—Fatigue—Doxorubicin—peripheral nervous system neoplasm	6.1e-05	0.000193	CcSEcCtD
Aprepitant—Urticaria—Epirubicin—peripheral nervous system neoplasm	6.07e-05	0.000192	CcSEcCtD
Aprepitant—Pain—Doxorubicin—peripheral nervous system neoplasm	6.05e-05	0.000192	CcSEcCtD
Aprepitant—Constipation—Doxorubicin—peripheral nervous system neoplasm	6.05e-05	0.000192	CcSEcCtD
Aprepitant—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	6.04e-05	0.000191	CcSEcCtD
Aprepitant—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	6.04e-05	0.000191	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	6.01e-05	0.00268	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—VIP—peripheral nervous system neoplasm	5.99e-05	0.00267	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	5.89e-05	0.00262	CbGpPWpGaD
Aprepitant—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	5.83e-05	0.000185	CcSEcCtD
Aprepitant—TACR1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	5.79e-05	0.00258	CbGpPWpGaD
Aprepitant—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	5.78e-05	0.000183	CcSEcCtD
Aprepitant—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	5.63e-05	0.000178	CcSEcCtD
Aprepitant—Urticaria—Doxorubicin—peripheral nervous system neoplasm	5.62e-05	0.000178	CcSEcCtD
Aprepitant—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	5.59e-05	0.000177	CcSEcCtD
Aprepitant—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	5.59e-05	0.000177	CcSEcCtD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	5.55e-05	0.00247	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	5.53e-05	0.00246	CbGpPWpGaD
Aprepitant—Asthenia—Epirubicin—peripheral nervous system neoplasm	5.48e-05	0.000174	CcSEcCtD
Aprepitant—Pruritus—Epirubicin—peripheral nervous system neoplasm	5.41e-05	0.000171	CcSEcCtD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	5.37e-05	0.00239	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	5.25e-05	0.00234	CbGpPWpGaD
Aprepitant—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	5.23e-05	0.000166	CcSEcCtD
Aprepitant—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	5.21e-05	0.000165	CcSEcCtD
Aprepitant—Asthenia—Doxorubicin—peripheral nervous system neoplasm	5.07e-05	0.000161	CcSEcCtD
Aprepitant—Dizziness—Epirubicin—peripheral nervous system neoplasm	5.05e-05	0.00016	CcSEcCtD
Aprepitant—CYP3A5—Metabolism—PPIP5K2—peripheral nervous system neoplasm	5.02e-05	0.00224	CbGpPWpGaD
Aprepitant—Pruritus—Doxorubicin—peripheral nervous system neoplasm	5e-05	0.000159	CcSEcCtD
Aprepitant—Vomiting—Epirubicin—peripheral nervous system neoplasm	4.86e-05	0.000154	CcSEcCtD
Aprepitant—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	4.84e-05	0.000153	CcSEcCtD
Aprepitant—Rash—Epirubicin—peripheral nervous system neoplasm	4.82e-05	0.000153	CcSEcCtD
Aprepitant—Dermatitis—Epirubicin—peripheral nervous system neoplasm	4.81e-05	0.000153	CcSEcCtD
Aprepitant—Headache—Epirubicin—peripheral nervous system neoplasm	4.79e-05	0.000152	CcSEcCtD
Aprepitant—CYP3A7—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.69e-05	0.00209	CbGpPWpGaD
Aprepitant—Dizziness—Doxorubicin—peripheral nervous system neoplasm	4.68e-05	0.000148	CcSEcCtD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	4.59e-05	0.00204	CbGpPWpGaD
Aprepitant—Nausea—Epirubicin—peripheral nervous system neoplasm	4.54e-05	0.000144	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	4.5e-05	0.002	CbGpPWpGaD
Aprepitant—Vomiting—Doxorubicin—peripheral nervous system neoplasm	4.5e-05	0.000143	CcSEcCtD
Aprepitant—Rash—Doxorubicin—peripheral nervous system neoplasm	4.46e-05	0.000141	CcSEcCtD
Aprepitant—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	4.45e-05	0.000141	CcSEcCtD
Aprepitant—Headache—Doxorubicin—peripheral nervous system neoplasm	4.43e-05	0.00014	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	4.42e-05	0.00197	CbGpPWpGaD
Aprepitant—Nausea—Doxorubicin—peripheral nervous system neoplasm	4.2e-05	0.000133	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	4.15e-05	0.00185	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	4.07e-05	0.00181	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PPIP5K2—peripheral nervous system neoplasm	3.88e-05	0.00173	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	3.79e-05	0.00169	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	3.65e-05	0.00163	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	3.55e-05	0.00158	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PPIP5K2—peripheral nervous system neoplasm	3.54e-05	0.00158	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.49e-05	0.00155	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—GNS—peripheral nervous system neoplasm	3.39e-05	0.00151	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—HSD17B12—peripheral nervous system neoplasm	3.39e-05	0.00151	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	3.38e-05	0.00151	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	3.29e-05	0.00146	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—NME1—peripheral nervous system neoplasm	3.25e-05	0.00145	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	3.2e-05	0.00142	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.17e-05	0.00141	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—COX2—peripheral nervous system neoplasm	3.13e-05	0.00139	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.1e-05	0.00138	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	3.02e-05	0.00135	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	2.98e-05	0.00133	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.9e-05	0.00129	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.66e-05	0.00118	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.62e-05	0.00117	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.47e-05	0.0011	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—GNS—peripheral nervous system neoplasm	2.45e-05	0.00109	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.39e-05	0.00106	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—NME1—peripheral nervous system neoplasm	2.35e-05	0.00105	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.33e-05	0.00104	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—COX2—peripheral nervous system neoplasm	2.26e-05	0.00101	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.2e-05	0.000978	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	2.18e-05	0.00097	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.16e-05	0.00096	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—ENO2—peripheral nervous system neoplasm	2.05e-05	0.000915	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.04e-05	0.00091	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.03e-05	0.000905	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	1.99e-05	0.000885	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.94e-05	0.000865	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GNS—peripheral nervous system neoplasm	1.9e-05	0.000844	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—NME1—peripheral nervous system neoplasm	1.82e-05	0.000809	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—COX2—peripheral nervous system neoplasm	1.75e-05	0.000779	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—BCHE—peripheral nervous system neoplasm	1.74e-05	0.000773	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GNS—peripheral nervous system neoplasm	1.73e-05	0.00077	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.72e-05	0.000764	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.7e-05	0.000759	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	1.7e-05	0.000756	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—NME1—peripheral nervous system neoplasm	1.66e-05	0.000738	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.66e-05	0.000738	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—TH—peripheral nervous system neoplasm	1.63e-05	0.000727	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.61e-05	0.000715	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—COX2—peripheral nervous system neoplasm	1.6e-05	0.00071	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.58e-05	0.000702	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.56e-05	0.000695	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.55e-05	0.000689	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—ENO2—peripheral nervous system neoplasm	1.49e-05	0.000661	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GNS—peripheral nervous system neoplasm	1.48e-05	0.000658	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.42e-05	0.000632	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—NME1—peripheral nervous system neoplasm	1.42e-05	0.00063	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—COX2—peripheral nervous system neoplasm	1.36e-05	0.000607	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—GNAS—peripheral nervous system neoplasm	1.33e-05	0.000593	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—ABCB1—peripheral nervous system neoplasm	1.31e-05	0.000582	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.3e-05	0.000578	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—BCHE—peripheral nervous system neoplasm	1.26e-05	0.000559	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.21e-05	0.000538	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.2e-05	0.000533	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—TH—peripheral nervous system neoplasm	1.18e-05	0.000525	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ENO2—peripheral nervous system neoplasm	1.15e-05	0.000511	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	1.14e-05	0.000508	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	1.09e-05	0.000487	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	1.05e-05	0.000468	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ENO2—peripheral nervous system neoplasm	1.05e-05	0.000466	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TP53—peripheral nervous system neoplasm	9.92e-06	0.000442	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—BCHE—peripheral nervous system neoplasm	9.7e-06	0.000432	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—GNAS—peripheral nervous system neoplasm	9.63e-06	0.000429	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	9.49e-06	0.000422	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—ABCB1—peripheral nervous system neoplasm	9.45e-06	0.000421	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—SLC2A1—peripheral nervous system neoplasm	9.26e-06	0.000412	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—TH—peripheral nervous system neoplasm	9.12e-06	0.000406	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ENO2—peripheral nervous system neoplasm	8.95e-06	0.000398	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—BCHE—peripheral nervous system neoplasm	8.85e-06	0.000394	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—SLC2A1—peripheral nervous system neoplasm	8.44e-06	0.000376	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.38e-06	0.000373	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—TH—peripheral nervous system neoplasm	8.32e-06	0.00037	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—BCHE—peripheral nervous system neoplasm	7.56e-06	0.000337	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GNAS—peripheral nervous system neoplasm	7.45e-06	0.000332	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ABCB1—peripheral nervous system neoplasm	7.31e-06	0.000325	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	7.21e-06	0.000321	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—TH—peripheral nervous system neoplasm	7.11e-06	0.000317	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	6.91e-06	0.000307	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GNAS—peripheral nervous system neoplasm	6.79e-06	0.000302	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ABCB1—peripheral nervous system neoplasm	6.66e-06	0.000297	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	5.84e-06	0.00026	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GNAS—peripheral nervous system neoplasm	5.8e-06	0.000258	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ABCB1—peripheral nervous system neoplasm	5.69e-06	0.000254	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.57e-06	0.000248	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	5.49e-06	0.000244	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	4.48e-06	0.000199	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	4.39e-06	0.000196	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—AKT1—peripheral nervous system neoplasm	3.6e-06	0.00016	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—AKT1—peripheral nervous system neoplasm	2.6e-06	0.000116	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—AKT1—peripheral nervous system neoplasm	2.01e-06	8.95e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—AKT1—peripheral nervous system neoplasm	1.83e-06	8.16e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—AKT1—peripheral nervous system neoplasm	1.57e-06	6.97e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	1.21e-06	5.38e-05	CbGpPWpGaD
